CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [31] Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GA04779g)
    Brown, Jennifer R.
    O'Brien, Susan
    Kingsley, C. Daniel
    Eradat, Herbert
    Pagel, John M.
    Lymp, James
    Hirata, Jamie
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [32] Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
    Huber, Henriette
    Tausch, Eugen
    Schneider, Christof
    Edenhofer, Simone
    Von Tresckow, Julia
    Robrecht, Sandra
    Giza, Adam
    Zhang, Can
    Furstenau, Moritz
    Dreger, Peter
    Ritgen, Matthias
    Illmer, Thomas
    Illert, Anna Lena
    Duerig, Jan
    Boettcher, Sebastian
    Niemann, Carsten Utoft
    Kneba, Michael
    Fink, Anna-Maria
    Fischer, Kirsten
    Doehner, Hartmut
    Hallek, Michael
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    BLOOD, 2022, 140
  • [33] RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group
    Estenfelder, Sven
    Holland-Letz, Ann-Kathrin
    Tausch, Eugen
    Robrecht, Sandra
    Bahlo, Jasmin
    Goede, Valentin
    Opatrna, Veronika
    Ritgen, Matthias
    van Dongen, Jacques J. M.
    Langerak, Anton W.
    Fingerle-Rowson, Gunter
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Dohner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2017, 130
  • [34] INDIRECT TREATMENT COMPARISONS OF OBINUTUZUMAB (GA101) PLUS CHLORAMBUCIL (CLB) VERSUS BENDAMUSTINE AND VERSUS OFATUMUMAB PLUS CLB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Waterboer, T.
    Moreno, S. G.
    Shang, A.
    Becker, U.
    Wiesner, C.
    VALUE IN HEALTH, 2014, 17 (03) : A225 - A225
  • [35] Final Analysis of the Prospective Multicenter CLL2- GIVe Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
    Huber, H.
    Edenhofer, S.
    von, Tresckow J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [36] Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    von Tresckow, Julia
    Bahlo, Jasmin
    Robrecht, Sandra
    Engelke, Anja
    Langerbeins, Petra
    Fink, Anna-Maria
    Balke-Want, Hyatt
    Al-Sawaf, Othman
    Seiler, Till
    von Weikersthal, Ludwig Fischer
    Hebart, Holger
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara F.
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [37] Comparative Effectiveness of Ofatumumab (O) in Combination with Chlorambucil (Chl) Versus Bendamustine (B), and Obinutuzumab (GA101) or Rituximab (R) in Combination with Chlorambucil for Chronic Lymphocytic Leukaemia (CLL)
    Wolowacz, Sorrel E.
    Mitchell, Sarah
    Haiderali, Amin
    BLOOD, 2014, 124 (21)
  • [38] Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Von Tresckow, Julia
    Fink, Anna-Maria
    Braun, Gracia
    Robrecht, Sandra
    Zhang, Can
    Tausch, Eugen
    Mueller, Lothar
    Knauf, Wolfgang
    Al-Sawaf, Othman
    Pelzer, Benedikt
    Langerbeins, Petra
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2020, 136
  • [39] Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Ferra, Christelle
    Rios-Herranz, Eduardo
    de la Mata, Margarita Fernandez
    Delgado, Julio
    Andreu, Rafael
    Hernandez-Rivas, Jose angel
    Terol, Maria Jose
    Navarro, Almudena
    Vidriales, M. Belen
    Baltasar, Patricia
    De la Serna, Javier
    Ramirez, Angel
    Ballester, Carmen
    Moreno, Carol
    Garcia-Marco, Jose Antonio
    Cordoba, Raul
    Yanez, Lucrecia
    Casado, Luis Felipe
    Gonzalez, Marcos
    Bosch, Francesc
    ECLINICALMEDICINE, 2024, 73
  • [40] Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
    Cartron, Guillaume
    de Guibert, Sophie
    Dilhuydy, Marie-Sarah
    Morschhauser, Franck
    Leblond, Veronique
    Dupuis, Jehan
    Mahe, Beatrice
    Bouabdallah, Reda
    Lei, Guiyuan
    Wenger, Michael
    Wassner-Fritsch, Elisabeth
    Hallek, Michael
    BLOOD, 2014, 124 (14) : 2196 - 2202
12345